EARLY DATA FROM A PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN ASIAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Yen, C. [1 ]
Shen, Y. [2 ]
Shiah, H. [3 ]
Chen, J. [2 ]
Hsu, C. [2 ]
Hsu, C. [2 ]
Huang, D. C. [4 ]
Hocke, J. [5 ]
Su, W. [1 ]
Cheng, A. [2 ]
机构：
[1] Natl Cheng Kung Univ, Coll Med & Hosp, Tainan 70101, Taiwan
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Hlth Res Inst, Tainan, Taiwan
[4] Boehringer Ingelheim Taiwan Ltd, Oncol, Taipei, Taiwan
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Oncol, Biberach, Germany
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246 / 247
页数：2
相关论文
共 50 条
  • [21] Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment
    Ikeda, M.
    Otsuka, T.
    Ueno, H.
    Mitsunaga, S.
    Sugimoto, R.
    Muro, K.
    Saito, I.
    Sasaki, T.
    Inoue, K.
    Loembe, A. B.
    Okusaka, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S454 - S454
  • [22] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [23] Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
    Tim Eisen
    Yaroslav Shparyk
    Nicholas Macleod
    Robert Jones
    Gudrun Wallenstein
    Graham Temple
    Yasser Khder
    Claudia Dallinger
    Matus Studeny
    Arsene-Bienvenu Loembe
    Igor Bondarenko
    Investigational New Drugs, 2013, 31 : 1283 - 1293
  • [24] Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
    Eisen, Tim
    Shparyk, Yaroslav
    Macleod, Nicholas
    Jones, Robert
    Wallenstein, Gudrun
    Temple, Graham
    Khder, Yasser
    Dallinger, Claudia
    Studeny, Matus
    Loembe, Arsene-Bienvenu
    Bondarenko, Igor
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1283 - 1293
  • [25] A phase I study of BIBF 1120, an orally active triple angiolkinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies.
    Lee, CP
    Attard, G
    Poupard, L
    Nathan, PD
    de Bono, JS
    Temple, GMR
    Stefanic, MF
    Padhani, AR
    Judson, IR
    Rustin, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [26] Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
    Shiah, Her-Shyong
    Chao, Yee
    Chen, Li-Tzong
    Yao, Tzy-Jyun
    Huang, Jin-Ding
    Chang, Jang-Yang
    Chen, Pei-Jer
    Chuang, Tsai-Rong
    Chin, Yung-Hsin
    Whang-Peng, Jacqueline
    Liu, Tsang-Wu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 654 - 664
  • [27] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [28] Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
    Her-Shyong Shiah
    Yee Chao
    Li-Tzong Chen
    Tzy-Jyun Yao
    Jin-Ding Huang
    Jang-Yang Chang
    Pei-Jer Chen
    Tsai-Rong Chuang
    Yung-Hsin Chin
    Jacqueline Whang-Peng
    Tsang-Wu Liu
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 654 - 664
  • [29] Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)
    Blaszkowsky, L. S.
    Abrams, T. A.
    Miksad, R. A.
    Zheng, H.
    Meyerhardt, J. A.
    Schrag, D.
    Kwak, E. L.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study
    Eisen, Tim
    Shparyk, Yaroslav
    MacLeod, Nicholas James
    Wallenstein, Gudrun
    Temple, Graham
    Khder, Yasser
    Dallinger, Claudia
    Studeny, Matus
    Loembe, Arsene Bienvenu
    Bondarenko, Igor N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345